Consultative Approach to Pharmaceutical Outsourcing

This document is a Q&A format article discussing best practices for outsourcing development and manufacturing (D&M) programs in the pharmaceutical industry. It features insights from Shawn Cain and Louise Carpenter of PCI Pharma Services, who emphasize the importance of selecting the right contract development and manufacturing organization (CDMO) partner. The article outlines essential attributes of a CDMO, including the ability to conduct small-scale development and in-house scalability for late-stage clinical and commercial supply. It highlights the necessity of strong cross-functional collaboration and effective analytical capabilities to ensure successful D&M. The authors address common challenges faced by CDMOs, such as lack of transparency from clients and unrealistic timelines, which can hinder project success. Additionally, they provide recommendations for sponsors to maximize D&M efficiency, including early communication with CDMOs and conducting stability studies. The overall focus is on ensuring a smooth drug product lifecycle from development to commercialization.